Abstract: The present invention relates to oligomeric compounds comprising at least two peptide moieties that bind specifically to proteoglycans, their payload conjugates and pharmaceutical compositions containing the same. Instant compounds, payload conjugates and pharmaceutical compositions are particularly useful in the treatment of cancer and in diagnostics.
Type:
Application
Filed:
December 18, 2021
Publication date:
April 4, 2024
Applicant:
PHI PHARMA SA
Inventors:
Christoph BONNY, Luc OTTEN, Andreas PEER, Marc MATHIEU, Alessandro ZORZI
Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
January 8, 2019
Assignee:
PHI PHARMA SA
Inventors:
Christophe Bonny, Fabrice Chenaux, Vincent Zoete
Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
November 20, 2018
Assignee:
PHI PHARMA SA
Inventors:
Christophe Bonny, Fabrice Chenaux, Vincent Zoete
Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides and polypeptides, which may act as transporter molecules that specifically recognize proteoglycans, in particular, chondroitin-4-sulfate (C4S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C4S expressing cells in vitro and in vivo.